The kidneys play a big part in controlling blood pressure. In fact, many of the major hypertensive medications have the root of their actions located in the kidneys. Diuretics work there, ACE inhibitors work there, as do the ARB’s, Spironolactone, and Triamterene. Over the past 18-20 months we have been …

Type 1 diabetes (T1DM) is one of the most prevalent severe chronic diseases of childhood, affecting more than 170,000 children in the United States, an increase of 23% since 2001. In the US, more than 25,000 children are diagnosed annually with 1:200 children and 1:100 adults diagnosed with T1DM during the lifespan.

In part three of this exclusive interview, Dr. Don Fetterolf talks about the use of amniotic membrane in the healing of diabetic foot ulcers and the process of using the placenta to create the graphs.

In this week's Homerun Slides, pathogenesis and biological interventions in autoimmune diabetes.

There are times that patients think that, magically, they start doing things right and their diabetes improves. We have all seen the obese diabetes patient who has started losing weight and feels they are doing well, only to find out that the weight loss is coming from the failure of …

Knowing the stability of their insulin medications is key to patients’ ability to control their blood sugar levels. When should your patients dispose of their insulin if refrigerated, non-refrigerated, opened or still sealed? Print out this stability chart of vials and insulin pens to hand out to your patients. Insulin Stability …

I was traveling this past week and it seemed that almost every person was wearing some kind of fitness tracking device. As I was going through the Atlanta airport, I watched people checking their devices and commenting on their steps while they were walking underground between terminals. When I sat on the plane, …

Research study finds high levels of glucose could be affecting kidneys even prior to diabetes diagnosis.

Patients with diabetes two to four times more likely to have heart complications than those without.

Basal insulin peglispro, lacking peripheral action, was compared to insulin glargine in a 52-week trial in type 2 diabetic patients previously treated with basal insulin.